Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusional Hemosiderosis”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Testing effectiveness (Phase 2)Study completedNCT01044186
What this trial is testing

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Who this might be right for
Transfusional Iron Overload
Novartis Pharmaceuticals 30
Testing effectiveness (Phase 2)Study completedNCT00395629
What this trial is testing

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Who this might be right for
Iron OverloadHereditary Hemochromatosis
Novartis Pharmaceuticals 49
Testing effectiveness (Phase 2)Study completedNCT00600938
What this trial is testing

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Who this might be right for
Transfusional Iron OverloadTransfusional Hemosiderosis
Novartis Pharmaceuticals 197
Large-scale testing (Phase 3)Study completedNCT00171171
What this trial is testing

Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Who this might be right for
Beta-ThalassemiaHemosiderosis
Novartis 252
Large-scale testing (Phase 3)UnknownNCT01511848
What this trial is testing

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Who this might be right for
Beta-thalassemia MajorSickle Cell DiseaseIron Hemosiderosis
Ain Shams University 60
Post-approval studies (Phase 4)Study completedNCT00481143
What this trial is testing

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Who this might be right for
Myelodysplastic SyndromesTransfusion Dependent Iron Overload
Novartis Pharmaceuticals 63
Post-approval studies (Phase 4)Study completedNCT00171301
What this trial is testing

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Who this might be right for
Beta-thalassemia MajorHemosiderosisIron Overload+1 more
Novartis Pharmaceuticals 233
Testing effectiveness (Phase 2)Study completedNCT00067080
What this trial is testing

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Anemia, Sickle Cell
Novartis Pharmaceuticals 195
Testing effectiveness (Phase 2)Study completedNCT01090323
What this trial is testing

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Who this might be right for
Sickle Cell Disease
Novartis Pharmaceuticals 185
Post-approval studies (Phase 4)Study completedNCT00654589
What this trial is testing

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Who this might be right for
Iron Overload
Novartis Pharmaceuticals 75
Testing effectiveness (Phase 2)WithdrawnNCT01927913
What this trial is testing

Treatment of Iron Overload Requiring Chelation Therapy

Who this might be right for
Transfusional Iron OverloadIron OverloadIron Chelation+4 more
Shire
Not applicableStudy completedNCT01394029
What this trial is testing

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Who this might be right for
Transfusional Hemosiderosis
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Study completedNCT00303329
What this trial is testing

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Who this might be right for
AnemiaHemosiderosis
Novartis Pharmaceuticals 184
Testing effectiveness (Phase 2)WithdrawnNCT01892644
What this trial is testing

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Who this might be right for
HemochromatosisMyelodysplastic Syndromes
Haukeland University Hospital
Testing effectiveness (Phase 2)Study completedNCT00061763
What this trial is testing

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

Who this might be right for
Beta-thalassemiaMyelodysplastic SyndromesFanconi Syndrome+2 more
Novartis Pharmaceuticals 175
Not applicableStudy completedNCT00466063
What this trial is testing

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Who this might be right for
Anemia
Novartis Pharmaceuticals 108
Large-scale testing (Phase 3)Study completedNCT00469560
What this trial is testing

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Who this might be right for
Myelodysplastic SyndromesHemosiderosis
Gruppo Italiano Malattie EMatologiche dell'Adulto 158
Large-scale testing (Phase 3)Study completedNCT00061750
What this trial is testing

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Beta-Thalassemia
Novartis Pharmaceuticals 595
Testing effectiveness (Phase 2)Study completedNCT00631163
What this trial is testing

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Who this might be right for
Chronic AnemiaTransfusional Hemosiderosis
Novartis Pharmaceuticals 102
Post-approval studies (Phase 4)Study completedNCT00845871
What this trial is testing

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Who this might be right for
Transfusional Hemosiderosis
Novartis Pharmaceuticals 65
Load More Results